CNS Pharmaceuticals, Inc. Write off of Deferred Debt Issuance Cost
CNS Pharmaceuticals, Inc. (CNSP) reported Write off of Deferred Debt Issuance Cost of $0 for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2020-08-10
- 2020-06-30: Write off of Deferred Debt Issuance Cost 6 month $0.00.
- 2019-06-30: Write off of Deferred Debt Issuance Cost 6 month $102.22K.
| Period end | Write off of Deferred Debt Issuance Cost 6 month |
|---|---|
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 |
| 2019-06-30 | $102.22K 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |